ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed
Kanwal P. S. Raghav
Matched on ORCID iD 0000-0003-1311-4173; OpenAlex author ID A5015321333, A5032970786. Sources: ClinicalTrials.gov.
Their work
- Papers
- 3
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2017: 1 trial · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper
Papers 3
- Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Co-author DOI 10.21037/jgo-20-569↗
- Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.3229↗
- Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Co-author DOI 10.1016/j.pan.2020.01.005↗
Trials 1
- Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Principal investigator NCT03074513↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael James Overman · 3 shared papers, 2020–2021 · strength 0.32
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Rachna T. Shroff · 3 shared papers, 2020–2021 · strength 0.32
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Milind M. Javle · 3 shared papers, 2020–2021 · strength 0.32
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Jonathan D. Mizrahi · 3 shared papers, 2020–2021 · strength 0.32
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Robert A. Wolff · 3 shared papers, 2020–2021 · strength 0.32
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Jane Elizabeth Rogers · 3 shared papers, 2020–2021 · strength 0.32
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Gauri Rajani Varadhachary · 3 shared papers, 2020–2021 · strength 0.32
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- Shubham Pant · 3 shared papers, 2020–2021 · strength 0.32
- Paper Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. DOI 10.21037/jgo-20-569↗
- Paper Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. DOI 10.1016/j.pan.2020.01.005↗
- Paper Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.3229↗
- David R. Fogelman · 2 shared papers, 2020 · strength 0.20
- Graciela M. Nogueras‐González · 1 shared paper, 2021 · strength 0.12
- Rishi Surana · 1 shared paper, 2021 · strength 0.12
- Kenneth R. Hess · 1 shared paper, 2020 · strength 0.10
- Linus Ho · 1 shared paper, 2020 · strength 0.10
- Chirayu Mohindroo · 1 shared paper, 2020 · strength 0.10
- Florencia M. McAllister · 1 shared paper, 2020 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.